Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline | Ophthalmology Times

The final segment highlights the rapidly evolving pipeline of retinal vascular disease therapies and offers closing reflections from the panelists. The discussion emphasizes the promise of next-generation agents, including sustained-release implants, tyrosine kinase inhibitors (TKIs), and gene therapies. TKIs are viewed as the most imminent advancement, potentially shifting care toward maintenance-based approaches by providing continuous VEGF inhibition with reduced injection frequency. Gene therapy is described as the “holy grail” for long-term disease control, with the potential to turn the eye into a self-sustaining biologic factory. The experts also acknowledge logistical and reimbursement challenges that may shape adoption. Despite uncertainties, optimism prevails: the field is on the brink of a paradigm shift offering unprecedented durability and convenience. The program concludes with reflections on clinical progress, enthusiasm for innovation, and a shared commitment to improving patient outcomes through advancing science and technology.